Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Cancer Res. 2020 Jan 3;80(5):1024–1035. doi: 10.1158/0008-5472.CAN-19-2560

Fig. 5. JQ1 sensitive Brd4 binding profiles and effects of BET inhibitor or/and dinaciclib on CLB-GA cells.

Fig. 5.

(A, B) Effects of dinaciclib and JQ1 on the mRNA expression of genes shown in CLB-GA cells. Cells were untreated or treated with 10 nM dinaciclib or 0.5 μM JQ1 for 8 or 20 h, respectively, followed by RT-qPCR analysis. The relative levels of mRNA expression were normalized to the GAPDH level and were expressed as fold changes relative to control (set at 1). (C, D, E) Effects of JQ1, dinaciclib, or AZD5153 on the cytotoxicity of human NB cell lines. Cells were treated with JQ1 (C, E), dinaciclib (D), or AZD5153 (E) at the indicated concentrations for 72 h, followed by MTS assay. (F, G) Additive or synergistic effects of JQ1/AZD5153 in combination with dinaciclib. CLB-GA cells were treated with JQ1, AZD5153, or dinaciclib alone or combination at the indicated concentrations for 72 h, followed by MTS assay. Asterisk or hash is in relation to control or dinaciclib treatment alone, respectively.